Memorial Sloan Kettering Cancer Center
Society presents awards for excellence in oncology nursing
The Oncology Nursing Society presented excellence awards to four individuals in recognition of their contributions to the field of oncology nursing.
CAR-T pioneer receives American Society of Gene and Cell Therapy’s highest honor
Michel Sadelain, MD, PhD, will receive this year’s Outstanding Achievement Award from the American Society of Gene and Cell Therapy for his research on chimeric antigen receptors.
Occult brain metastases found in about 4% of patients with advanced kidney cancer
About 4% of patients with advanced renal cell carcinoma had asymptomatic brain metastases, according to results of a retrospective multi-institutional cohort study published in Journal of the National Comprehensive Cancer Network.
Oncology nurses recognized for ‘making a difference’
Researcher develops novel sensor for early detection of ovarian cancer
Mijin Kim, PhD, has been selected to receive a 2021 Marie-Josée Kravis Women in Science Endeavor fellowship grant for her work on a novel sensor technology designed for early detection of ovarian cancer.
Neoadjuvant cemiplimab leads to tumor necrosis in HCC
More than one-third of a small cohort patients with early-stage hepatocellular carcinoma achieved at least 50% tumor necrosis following neoadjuvant treatment with cemiplimab, results of a phase 2a trial showed.
Personalized vaccine shows potential benefit across cancer types
A personalized genomic vaccine administered after standard-of-care adjuvant therapy appeared safe and induced immunogenicity among patients with different cancers at a high risk for recurrence, according to results of a phase 1 trial.
Copanlisib-rituximab combination extends PFS in relapsed indolent non-Hodgkin lymphoma
The addition of copanlisib to rituximab increased response rates and significantly extended PFS among patients with relapsed indolent non-Hodgkin lymphoma, according to study results.
Cell therapy promising for Epstein-Barr virus-driven post-HSCT lymphoproliferative disease
More than 80% of patients who responded to therapy with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease remained alive 2 years after initial treatment, study results showed.
José Baselga, head of oncology R&D for AstraZeneca and ‘true change-maker,’ dies at 61
Prominent cancer researcher José Baselga, MD, PhD, FASCO, who served as head of oncology research and development for AstraZeneca, has died at age 61 years, the company announced in a press release.